Our group previously used a PLGA scaffold to deliver CD40-targeted mini-tLivin nanoparticles, achieving durable tumor regression in a disseminated DLBCL mouse model [24]. This evidence concerns the gene CD40 and diffuse large B-cell lymphoma.